Skip to main content

Candel Therapeutics, Inc.

corporate_fare Company Profile

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed CADL - Latest Insights

CADL
Apr 29, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
CADL
Apr 29, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
CADL
Mar 18, 2026, 4:23 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
CADL
Mar 17, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
CADL
Mar 12, 2026, 8:17 AM EDT
Filing Type: 10-K
Importance Score:
9
CADL
Mar 12, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
CADL
Feb 26, 2026, 7:38 PM EST
Filing Type: 4
Importance Score:
9
CADL
Feb 23, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
CADL
Feb 20, 2026, 4:16 PM EST
Filing Type: 424B5
Importance Score:
8
CADL
Feb 19, 2026, 4:31 PM EST
Filing Type: 424B5
Importance Score:
8
CADL
Feb 19, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
9